Staff

TOP 5 publications:

1. Gründer G, Mertens L, Jungaberle A, Jungaberle H, Spangemacher M. Compassionate use of psilocybin for treatment-resistant depression in Germany.Lancet Psychiatry. 2025 Sep 18. [Epub ahead of print].
2. Gründer G, Brand M, Mertens L, Jungaberle H, Kärtner L, Scharf DJ, Spangemacher M, Wolff M. Treatment with psychedelics is psychotherapy: beyond reductionism.Lancet Psychiatry. 2024 11(3):231-236. Epub 2023 Dec 12.
3. Spangemacher M, Mertens L, Färber LV, Jungaberle A, Jungaberle H, Gründer G. Psilocybin as a Disease-Modifying Drug—a Salutogenic Approach in Psychiatry.Dtsch Arztebl Int. 2024 121(26):868-874. Epub 2024 Dec 27.
4. Spangemacher M, Schmitz C, Cumming P, Färber LV, Hart XM, Uchida H, Gründer G. The sense and nonsense of antipsychotic combinations: A model for dopamine D receptor occupancy.Transl Psychiatry. 2025 15(1):348.
5. Pedraz-Petrozzi B, Spangemacher M, Deicher A, Drews L, Defert J, Silva-Colmenero AY, Wein P, Riedinger E, Gründer G, Gilles M, Sartorius A, Reinwald JR. Baseline monocyte count predicts symptom improvement during intravenous ketamine therapy in treatment-resistant depression: a single-arm open-label observational study.Front Psychiatry. 2024 15:1415505.